(Adnkronos) – “The ‘Select’ study tells us that the drug semaglutide can produce significant weight loss in overweight or obese adults who do not have diabetes, reducing cardiovascular events independently of weight loss. The study took into account examination of obese – but not diabetic – patients who had already had a myocardial infarction or a stroke to verify whether semaglutide 2.4 mg administered under the skin weekly could reduce cardiovascular events compared to placebo, i.e. compared to all those drugs that these patients must take. In the group treated with semaglutide, a 20% reduction in cardiovascular events was found, therefore an excellent result that opens up a whole series of perspectives”. Tor Vergata Rome on the sidelines of the European Endocrinology Congress in Venice.
#Sbraccia #Tor #Vergata #Semaglutide #obesity #reduces #cardiovascular #risk
Sbraccia (Tor Vergata): “Semaglutide against obesity reduces cardiovascular risk”
